Albuminomics

Effective Albumin – A Novel Paradigm in the Management of Decompensated Liver Cirrhosis

3 min read

Effective Albumin – A Novel Paradigm in the Management of Decompensated Liver Cirrhosis

Bibliographic info

  • Authors: Mauro Bernardi
  • Journal: Journal of Translational Internal Medicine, 2023, vol. 11, no. 1, pp. 11–14; DOI: 10.2478/jtim-2022-0070
  • Institution: Department of Medical and Surgical Sciences, University of Bologna, Italy

Key question (perspective)

Does the concept of effective albumin (eAlb) — the fraction of structurally and functionally intact albumin — represent a clinically useful paradigm shift in managing decompensated cirrhosis?

Content (perspective article)

HSA biology recap

  • 66.5 kDa; 585 aa; synthesized by hepatocytes; 3.5–5 g/dL in healthy adults; 10–15 g/day production; inhibited by IL-6/TNF-α
  • Non-oncotic functions: antioxidant (Cys34 thiol), binding/transport (drugs, bilirubin, FAs), endothelial stabilization, immunomodulation (PGE2 inactivation, complement inhibition, macrophage dysfunction prevention), hemostasis (platelet aggregation reduction), acid-base buffering

Pathophysiology of advanced cirrhosis (context for eAlb concept)

  • Arterial vasodilation (splanchnic) → effective hypovolemia → RAAS/SNS activation → sodium retention → ascites/edema
  • Additionally: systemic inflammation → progressive organ failure → ACLF
  • Both mechanisms drive HSA structural damage (oxidative stress + inflammation → PTMs)

The effective albumin concentration (EAc) concept

  • eAlb = tAlb × native HSA fraction (LC-MS)
  • Traditional tAlb measurement (BCG or BCP colorimetric method) measures ALL albumin regardless of structural state → can’t distinguish functional from dysfunctional
  • EAc addresses this: captures the proportion with preserved structure and function
  • EAc declines progressively: compensated → AD → ACLF (more than tAlb)

Key clinical evidence cited (from baldassarre-2021-ealb)

  1. eAlb declines progressively with cirrhosis severity, superior to tAlb in stratifying stages
  2. eAlb better reflects albumin binding and detoxification activity (EPR correlation)
  3. eAlb at admission predicts 30-day ACLF occurrence better than tAlb
  4. eAlb at admission predicts 90-day mortality better than tAlb

Therapeutic implications of eAlb

  • Target eAlb rather than tAlb for albumin infusion decisions
  • eAlb level may indicate extent of albumin dysfunction → guide drug dosing (free fraction consequences)
  • Monitoring eAlb response could assess treatment efficacy

Immunomodulatory mechanism (referenced)

  • HNA1 triggers cytokine storm via p38 MAPK → alcaraz-quiles-2018
  • Non-mercaptalbumin fractions enhance IL-6/TNF-α production → inflammatory amplification

Clinical context

  • Disease: Decompensated Liver fibrosis / ACLF
  • Position in field: This 2023 perspective formalizes the eAlb concept as a clinical paradigm, positioned as the summary statement from the Bologna group’s years of work (Domenicali 2014 → Baldassarre 2021 → Bernardi 2023)

Connections

  • HSA — effective albumin concept definition and clinical evidence
  • baldassarre-2021-ealb — the primary data paper that established eAlb clinical validity
  • domenicali-2014 — foundational: native HSA as survival predictor; the basis of eAlb concept
  • spinella-2016-review — complementary UCL perspective on effective albumin (earlier review)
  • alcaraz-quiles-2018 — HNA1 inflammatory mechanism cited in support of eAlb clinical relevance
  • fernandez-2019 — albumin therapy; non-oncotic effects
  • el-balkhi-2025 — ALBOM applies isoform profiling approach that operationalizes eAlb concept for CLD fibrosis staging

Take home notes

  • Bernardi is the senior author / PI of the Bologna group. This perspective is the group’s authoritative summary statement positioning eAlb as the new clinical standard.
  • The phrase “effective albumin” vs “total albumin” is the core paradigm shift: move from quantity (g/L measured by colorimetric assay) to quality-adjusted quantity (native fraction × total). This is exactly what el-balkhi-2025 measures with absolute quantification.
  • The clinical evidence is strong: eAlb outperforms tAlb for ACLF prediction and 90-day mortality. The regulatory/clinical adoption pathway will require standardization of the LC-MS measurement — something our CQFD-PTM pipeline and PTM-CQFD project are positioning to address.
  • This 4-page perspective is the best concise summary for a non-expert audience of why eAlb matters. Suitable citation for grant applications.

Graph View

Backlinks